Clinical Trials Using Dabrafenib Mesylate

Clinical trials are research studies that involve people. The clinical trials on this list are studying Dabrafenib Mesylate. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-10 of 10
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1191 locations

  • Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAFV600 Melanoma

    This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.
    Location: 715 locations

  • Dabrafenib Combined with Trametinib after Radiation Therapy in Treating Patients with Newly-Diagnosed High-Grade Glioma

    This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.
    Location: 59 locations

  • Trametinib with or without Dabrafenib Mesylate in Treating Patients with BRAF, KRAS, or NRAS Gene Mutation and Recurrent Multiple Myeloma

    This phase II trial studies how well trametinib with or without dabrafenib mesylate works in treating patients with BRAF, KRAS, or NRAS gene mutation and multiple myeloma that has come back. Trametinib and dabrafenib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: 7 locations

  • Pembrolizumab and Trametinib with or without Dabrafenib in Treating Patients with Melanoma That Is Metastatic or Cannot Be Removed by Surgery

    This phase II trial studies how well pembrolizumab and trametinib with or without dabrafenib work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib with or without dabrafenib may work better in treating patients with melanoma.
    Location: 3 locations

  • MCS110, Dabrafenib Mesylate, and Trametinib in Treating Patients with BRAF V600E or V600K Mutated Melanoma

    This phase I / II trial studies the best dose and side effects of anti-M-CSF monoclonal antibody MCS110 (MCS110) and how well it works when given together with dabrafenib mesylate and trametinib in treating patients with BRAF V600E or V600K mutated melanoma. Immunotherapy with monoclonal antibodies, such as MCS110, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Dabrafenib mesylate and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving MCS110, dabrafenib mesylate and trametinib may work better at treating BRAF V600E or V600K mutated melanoma.
    Location: 2 locations

  • Testing the Safety and Benefit of Adding Hydroxychloroquine to Dabrafenib and / or Trametinib in Children with Recurrent or Progressive Low Grade or High Grade Brain Tumor with Specific Genetic Mutations

    This phase I / II trial studies the side effects and best dose of adding hydroxychloroquine to dabrafenib and / or trametinib, and to see how well they work in treating children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion / duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and / or dabrafenib may lower the chance of brain tumors from growing or spreading compared to usual treatments.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York

  • Dabrafenib and Trametinib in Treating Patients with Erdheim Chester Disease with BRAF V600 Mutations

    This phase II trial studies the side effects and how well dabrafenib and trametinib work in treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Itacitinib, Dabrafenib Mesylate, and Trametinib in Treating Participants with BRAF-Mutant Metastatic or Unresectable Melanoma or Solid Tumors

    This phase I trial studies the sides effects and best dose of itacitinib when given together with dabrafenib mesylate and trametinib in treating participants with BRAF-mutant melanoma and solid tumors that have spread to other places in the body or cannot be removed by surgery. Itacitinib, dabrafenib mesylate, and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts

  • Dabrafenib Mesylate, Trametinib, and 6 Melanoma Helper Peptide Vaccine in Treating Patients with Stage IIIB-IV Melanoma

    This phase I / II trial studies the side effects and how well dabrafenib mesylate, trametinib, and 6 melanoma helper peptide vaccine work in treating patients with stage IIIB-IV melanoma. Dabrafenib mesylate and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines, such as 6 melanoma helper peptide vaccine, made from peptides derived from melanoma proteins, may help the body build an effective immune response to kill tumor cells that express melanoma-specific antigens. Giving dabrafenib, trametinib, and 6 melanoma helper peptide vaccine may work better in treating patients with melanoma.
    Location: University of Virginia Cancer Center, Charlottesville, Virginia